TRDA supply chain intelligence for Entrada Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| SUPPLIERS | SUPPLIERS | 92% | We currently rely on third-party contract manufacturing organizations ("CMOs"), and suppliers for EEV peptides, including linkers, and nucleotides that comprise ENTR-601-44, ENTR 601-45, ENTR-601-50,… |
| THIRD-PARTY-CONTRACT-MANUFACTURING-ORGANIZATIONS | THIRD-PARTY-CONTRACT-MANUFACTURING-ORGANIZATIONS | 92% | We currently rely on third-party contract manufacturing organizations ("CMOs"), and suppliers for EEV peptides, including linkers, and nucleotides that comprise ENTR-601-44, ENTR 601-45, ENTR-601-50,… |
| THIRD-PARTY-VENDORS | THIRD-PARTY-VENDORS | 90% | We engage a number of third-party suppliers and service providers to supply critical goods and services, such as contract research services, contract manufacturing services and information technology… |
| FOREIGN-CROS-AND-CMOS | FOREIGN-CROS-AND-CMOS | 85% | We currently rely on foreign CROs and CMOs to manufacture our clinical materials, and may rely on foreign CROs and CMOs in the future. |
| BMRN | BioMarin Pharmaceutical Inc. | 72% | everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be … |
| BMRN | BioMarin Pharmaceutical Inc. | 72% | Reciprocal relationship from BMRN graph: Reciprocal relationship from TRDA graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from TRDA graph: everal risks, including disruptions… |
| DSGN | Design Therapeutics, Inc. | 72% | everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be … |
| DSGN | Design Therapeutics, Inc. | 72% | Reciprocal relationship from DSGN graph: Reciprocal relationship from TRDA graph: everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively … |
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: Reciprocal relationship from TRDA graph: Reciprocal relationship from DYN graph: Reciprocal relationship from TRDA graph: Reciprocal relationship from DYN grap… |
| DYN | Dyne Therapeutics, Inc. | 72% | everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be … |
| PTCT | PTC Therapeutics, Inc. | 72% | everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be … |
| PTCT | PTC Therapeutics, Inc. | 72% | Reciprocal relationship from PTCT graph: Reciprocal relationship from TRDA graph: everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively … |
| RNAM | RNAM | 72% | Reciprocal relationship from RNAM graph: Reciprocal relationship from TRDA graph: everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively … |
| RNAM | RNAM | 72% | everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be … |
| SLDB | Solid Biosciences Inc. | 72% | Reciprocal relationship from SLDB graph: Reciprocal relationship from TRDA graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from TRDA graph: everal risks, including disruptions… |
| SLDB | Solid Biosciences Inc. | 72% | everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be … |
| SRPT | Sarepta Therapeutics, Inc. | 72% | Reciprocal relationship from SRPT graph: Reciprocal relationship from TRDA graph: everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively … |
| SRPT | Sarepta Therapeutics, Inc. | 72% | everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be … |
| VRTX | Vertex Pharmaceuticals Incorporated | 72% | Reciprocal relationship from VRTX graph: Research and development expenses .” We also share with CRISPR % of the net commercial profits or losses incurred with respect to CASGEVY, subject to certain … |
| VRTX | Vertex Pharmaceuticals Incorporated | 72% | ng a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. In 2026, we expect to progress our ENTR-601-44 and EN… |
| WVE | Wave Life Sciences Ltd. | 72% | everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be … |
| WVE | Wave Life Sciences Ltd. | 72% | Reciprocal relationship from WVE graph: Reciprocal relationship from TRDA graph: everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively f… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BMRN | BioMarin Pharmaceutical Inc. | 72% | f treatment with our therapeutics in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government … |
| BMRN | BioMarin Pharmaceutical Inc. | 72% | Reciprocal relationship from BMRN graph: Reciprocal relationship from TRDA graph: f treatment with our therapeutics in relation to alternative treatments and therapies; • our ability to obtain and ma… |
| DSGN | Design Therapeutics, Inc. | 72% | f treatment with our therapeutics in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government … |
| DSGN | Design Therapeutics, Inc. | 72% | Reciprocal relationship from DSGN graph: Reciprocal relationship from TRDA graph: Reciprocal relationship from DSGN graph: Reciprocal relationship from TRDA graph: Reciprocal relationship from DSGN g… |
| DYN | Dyne Therapeutics, Inc. | 72% | f treatment with our therapeutics in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government … |
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number… |
| PTCT | PTC Therapeutics, Inc. | 72% | f treatment with our therapeutics in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government … |
| PTCT | PTC Therapeutics, Inc. | 72% | Reciprocal relationship from PTCT graph: Reciprocal relationship from TRDA graph: Reciprocal relationship from PTCT graph: Reciprocal relationship from TRDA graph: Reciprocal relationship from PTCT g… |
| RNAM | RNAM | 72% | f treatment with our therapeutics in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government … |
| RNAM | RNAM | 72% | Reciprocal relationship from RNAM graph: Reciprocal relationship from TRDA graph: Reciprocal relationship from RNAM graph: Reciprocal relationship from TRDA graph: f treatment with our therapeutics i… |
| SLDB | Solid Biosciences Inc. | 72% | Reciprocal relationship from SLDB graph: Reciprocal relationship from TRDA graph: f treatment with our therapeutics in relation to alternative treatments and therapies; • our ability to obtain and ma… |
| SLDB | Solid Biosciences Inc. | 72% | f treatment with our therapeutics in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government … |
| SRPT | Sarepta Therapeutics, Inc. | 72% | Reciprocal relationship from SRPT graph: Reciprocal relationship from TRDA graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from TRDA graph: Reciprocal relationship from SRPT g… |
| SRPT | Sarepta Therapeutics, Inc. | 72% | f treatment with our therapeutics in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government … |
| VRTX | Vertex Pharmaceuticals Incorporated | 72% | ng a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. In 2026, we expect to progress our ENTR-601-44 and EN… |
| VRTX | Vertex Pharmaceuticals Incorporated | 72% | Reciprocal relationship from VRTX graph: Reciprocal relationship from TRDA graph: ng a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited ret… |
| WVE | Wave Life Sciences Ltd. | 72% | Reciprocal relationship from WVE graph: Reciprocal relationship from TRDA graph: f treatment with our therapeutics in relation to alternative treatments and therapies; • our ability to obtain and mai… |
| WVE | Wave Life Sciences Ltd. | 72% | f treatment with our therapeutics in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| TRDA-DEBT | Debt stack $49.8M | 90% | Market cache reports total debt of $49.8M. |
| TRDA-DEBT-13093 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2021-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| TRDA-OWNER-BAKER-BROS-ADVISORS-LP | BAKER BROS. ADVISORS LP | 90% | 13F overlay lists BAKER BROS. ADVISORS LP as top holder; 119 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| TECX | Tectonic Therapeutic, Inc. | 100.00 | 2 | |
| CABA | Cabaletta Bio, Inc. | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| PSNL | Personalis, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| BCYC | Bicycle Therapeutics plc | 100.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CAPR | Capricor Therapeutics, Inc. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| HTGC | Hercules Capital, Inc. | 100.00 | 2 | |
| BNTC | Benitec Biopharma Inc. | 100.00 | 2 | |
| CALC | CalciMedica, Inc. | 100.00 | 2 | |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | |
| RGNX | REGENXBIO Inc. | 100.00 | 2 | |
| CLPT | ClearPoint Neuro, Inc. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| ELVN | Enliven Therapeutics, Inc. | 100.00 | 2 |